Nautilus Biotechnology, Inc. reported results for the 2026 quarter in a 10-Q filing, generating $190K of revenue and posting a net loss of ($14.47M), or diluted EPS of ($0.11), modestly improved from the prior-year quarter.Financial Highlights¹ Reported as “Total revenue”. ² Reported as “Net loss”…
Q2 2026 saw minimal revenue and a net loss of $14.5M, with ongoing investment in R&D and commercialization of the proteomics platform. Cash and investments of $129.2M are expected to fund operations for at least 12 months, but additional capital will be needed as losses continue and commercializati…
R&D focus shifted to proteoform applications due to strong customer demand and technical progress, with first revenue recognized from grants and early access. Operating expenses declined, cash runway extends into 2028, and commercial launch of the Voyager Platform is planned for 2027.Based on Nauti…
NAUT (Nautilus Biotechnology, Inc.) is set to announce its Q2'26 results on July 28, before the market opens. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q2'26, revenue estimate is 0 USD with EPS (earnings per share) anticipated at (0.14) USD. Learn more details at NA…
SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. NASDAQ:NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter 2026 before market open on Tuesday, July 28, 2026.The compan…
